Publications

Tap into Gubra’s vast production of publications and posters to get the latest knowledge and insights within our focus areas: diabetes, obesity, NASH and gastrointestinal diseases.

Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

Tanja X. Pedersen, Thea Johansen, Lisbeth N. Fink, Niels Vrang, Thomas Secher

Novel Rat Model of Diabetic Nephropathy Displaying Tubular Fibrosis and Glomerular Alterations

Thomas Secher, Thea Johansen, Mette V. Østergaard, Philip J. Pedersen, Nora E. Zois, Tanja X. Pedersen, Niels Vrang, Lisbeth N. Fink

Novel 'Dual Hit' Rat Model of Diabetic Cardiomyopathy

Louise Thisted, Ross T. Lindsay, Keld Fosgerau, Thomas Secher, Morten Bækgaard Thomsen, Thomas Jespersen, Andrew J. Murray, Philip J. Pedersen, Niels Vrang, Lisbeth N. Fink, Tanja X. Pedersen, Nora E. Zois

The Preprohomone Expression Profile Of Enteroendocrine Cells Following Roux-en-Y Gastic Bypass in Rats

Lise Christine Biehl Rudkjær, Chen Chang, Kristoffer Rigbolt, Mechthilde Falkenhahn, Stefan Theis, Thomas Hübschle, Niels Vrang, Jacob Jelsing

Chemical Strategies for Half-life Extension of Biopharmaceuticals: Lipidation and its Alternatives

Esben Bech, Søren L. Pedersen, Knud Jensen

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson’s Disease

Fabricius K, Barkholt P, Jelsing J, Hansen HH

Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2

Jelsing J, Galzin AM, Guillot E, Pruniaux MP, Larsen PJ, Vrang N

The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion

Jelsing J, Larsen PJ, Vrang N

The imprinted gene neuronatin is regulated by metabolic status and associated with obesity

Vrang N, Meyre D, Froguel P, Jelsing J, Tang-Christensen M, Vatin V, Mikkelsen JD, Thirstrup K, Larsen LK, Cullberg KB, Fahrenkrug J, Jacobson P, Sjöström L, Carlsson LM, Liu Y, Liu X, Deng HW, Larsen PJ

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

Vrang N, Larsen PJ

The brainstem preproglucagon system in a non-human primate (Macaca mulatta)

Vrang N, Grove K

Laser capture microdissection and quantitative-PCR analysis

Paulsen SJ, Larsen LK

Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight

Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Søeborg H, Knudsen LB

Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helixvariants of PYY3-36

Pedersen SL, Bhatia VK, Jurt S, Paulsson JF, Pedersen MH, Jorgensen R, Holst B, Stamou D, Vrang N, Zerbe O, Jensen KJ

Peptide release, side-chain deprotection, work-up, and isolation

Pedersen SL, Jensen KJ

Instruments for automated peptide synthesis

Pedersen SL, Jensen KJ

The effect of ileal interposition surgery on enteroendocrine cell numbers in the UC Davis type 2 diabetes mellitus rat

Hansen CF, Vassiliadis E, Vrang N, Sangild PT, Cummings BP, Havel P, Jelsing J

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

Hansen HH, Hansen G, Paulsen S, Vrang N, Mark M, Jelsing J, Klein T

Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis

Koehler JA, Baggio LL, Cao X, Abdulla T, Campbell JE, Secher T, Jelsing J, Larsen B, Drucker DJ

Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

Dalbøge LS, Pedersen SL, van Witteloostuijn SB, Rasmussen JE, Rigbolt KT, Jensen KJ, Holst B, Vrang N, Jelsing J

The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats

Skarbaliene J, Secher T, Jelsing J, Ansarullah, Neerup TS, Billestrup N, Fosgerau K

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes

Rhee NA, Wahlgren CD, Pedersen J, Mortensen B, Langholz E, Wandall EP, Friis SU, Vilmann P, Paulsen SJ, Kristiansen VB, Jelsing J, Dalbøge LS, Poulsen SS, Holst JJ, Vilsbøll T, Knop FK

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathyhttps://www.ncbi.nlm.nih.gov/pubmed/26746341

Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N

Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs

Hansen CF, Thymann T, Andersen AD, Holst JJ, Hartmann B, Hilsted L, Langhorn L, Jelsing J, Sangild PT

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease

Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP

Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

van Witteloostuijn SB, Pedersen SL, Jensen KJ

Neoglycolipids for prolonging the effects of peptides: Self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy

van Witteloostuijn SB, Mannerstedt K, Wismann P, Bech EM, Thygesen MB, Vrang N, Jelsing J, Jensen KJ, Pedersen SL

Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia

Mace ML, Gravesen E, Nordholm A, Hofman-Bang J, Secher T, Olgaard K, Lewin E

Neurturin and a GLP-1 analogue act synergistically to alleviate diabetes in Zucker diabetic fatty rats

Trevaskis JL, Sacramento CB, Jouihan H, Ali S, Le Lay J, Oldham S, Bhagroo N, Boland BB, Cann J, Chang Y, O'Day T, Howard V, Reers C, Winzell MS, Smith DM, Feigh M, Barkholt P, Schreiter K, Austen M, Andag U, Thompson S, Jermutus L, Coghlan MP, Grimsby J, Dohrmann C, Rhodes CJ, Rondinone CM, Sharma A

Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model

Helboe L, Egebjerg J, Barkholt P, Volbracht C

A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

Schneider EL, Hearn BR, Pfaff SJ, Reid R, Parkes DG, Vrang N, Ashley GW, Santi DV

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues

Bech EM, Martos-Maldonado MC, Wismann P, Sørensen KK, van Witteloostuijn SB, Thygesen MB, Vrang N, Jelsing J, Pedersen SL, Jensen KJ

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice

van Witteloostuijn SB, Dalbøge LS, Hansen G, Midtgaard SR, Jensen GV, Jensen KJ, Vrang N, Jelsing J, Pedersen SL

Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control

Fernandez-Cachon ML, Pedersen SL, Rigbolt KT, Zhang C, Fabricius K, Hansen HH, Elster L, Fink LN, Schäfer M, Rhee NA, Langholz E, Wandall E, Friis SU, Vilmann P, Kristiansen VB, Schmidt C, Schreiter K, Breitschopf K, Hübschle T, Jorsal T, Vilsbøll T, Schmidt T, Theis S, Knop FK, Larsen PJ, Jelsing J

Enteroendocrine K and L cells in healthy and type 2 diabetic individuals

Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, Jelsing J, Dalbøge LS, Vilmann P, Hassan H, Hendel JW, Poulsen SS, Holst JJ, Vilsbøll T, Knop FK

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

Pernille Wismann, Søren L. Pedersen, Gitte Hansen, Karin Mannerstedt, Philip J. Pedersen, Palle B. Jeppesen, Niels Vrang, Keld Fosgerau, Jacob Jelsing

INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Jonathan D. Roth, Michael Feigh, Sanne S. Veidal, Louise K.D. Fensholdt, Kristoffer T. Rigbolt, Henrik H. Hansen, Li C. Chen, Mathieu Petitjean, Weslyn Friley, Niels Vrang, Jacob Jelsing, Mark Young

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Kirstine S. Tølbøl, Maria N.B. Kristiansen, Henrik H. Hansen, Sanne S. Veidal, Kristoffer T.G. Rigbolt, Matthew P. Gillum, Jacob Jelsing, Niels Vrang, Michael Feigh

Body-weight lowering agents and their comparative metabolic and hepatic effects in obese mouse models of non-alcoholic fatty liver disease and steatohepatitis (Gubra poster)

Jacob Jelsing, Michael Feigh, Kirstine Sloth Tølbøl, Sanne Skovgård Veidal, and Niels Vrang

In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes (European Journal of Pharmacology)

Jolanta Skarbaliene, Kristoffer T. Rigbolt, Keld Fosgerau, Nils Billestrup

Mouse models of nonalcoholic steatohepatitis in preclinical drug development (Drug Discovery Today)

Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K.

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice (Molecular Metabolism)

Wismann P, Barkholt P, Secher T, Vrang N, Hansen HB, Jeppesen PB, Baggio LL, Koehler JA, Drucker DJ, Sandoval DA, Jelsing J.

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease (PLoS One)

Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N.

Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy (World Journal of Hepatology)

Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Kristoffer Tobias Gustav Rigbolt, Kirstine Sloth Tølbøl, Jacob Jelsing, Niels Vrang, Michael Feigh

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice (Journal of Diabetes Research)

Cucak H, Hansen G, Vrang N, Skarsfeldt T, Steiness E, Jelsing J.

Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass (Molecular Metabolism)

Barkholt P, Pedersen PJ, Hay-Schmidt A, Jelsing J, Hansen HH, Vrang N.

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents ((PLoS One))

Dalbøge LS, Pedersen PJ, Hansen G, Fabricius K, Hansen HB, Jelsing J, Vrang N.

Neuromedin U inhibits food intake partly by inhibiting gastric emptying (Peptides)

Dalbøge LS, Pedersen SL, Secher T, Holst B, Vrang N, Jelsing J.

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease (Journal of Alzheimer’s Disease)

Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, Pyke C, Knudsen LB, Farr SA, Vrang N.

Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain (Endocrinology)

Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, Knudsen LB, Vrang N, Grove KL.

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss (The Journal of Clinical Investigation )

Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L.

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat (The Journal of Pharmacology and Experimental Therapeutics)

Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, Klein T, Mayoux E.

The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice (The Journal of Pharmacology and Experimental Therapeutics)

Dalbøge LS, Almholt DL, Neerup TS, Vrang N, Jelsing J, Fosgerau K.

Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion (PLoS One)

Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N.

Characterisation of age-dependent beta cell dynamics in the male db/db mice (PLoS One)

Dalbøge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, Fosgerau K, Jelsing J.

Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats (PLoS One)

Hansen CF, Bueter M, Theis N, Lutz T, Paulsen S, Dalbøge LS, Vrang N, Jelsing J.

Novel insight into the distribution of L-cells in the rat intestinal tract (American Journal of Translational Research)

Hansen CF, Vrang N, Sangild PT, Jelsing J.

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice (Journal of Endocrinology)

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.

Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats (Acta Pharmacologica Sinica)

Hansen G, Jelsing J, Vrang N.

Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function (Journal of Anatomy)

Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J.

Featured publications

INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Jonathan D. Roth, Michael Feigh, Sanne S. Veidal, Louise K.D. Fensholdt, Kristoffer T. Rigbolt, Henrik H. Hansen, Li C. Chen, Mathieu Petitjean, Weslyn Friley, Niels Vrang, Jacob Jelsing, Mark Young

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Kirstine S. Tølbøl, Maria N.B. Kristiansen, Henrik H. Hansen, Sanne S. Veidal, Kristoffer T.G. Rigbolt, Matthew P. Gillum, Jacob Jelsing, Niels Vrang, Michael Feigh

Mouse models of nonalcoholic steatohepatitis in preclinical drug development (Drug Discovery Today)

Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K.

Publications

Tap into Gubra’s vast production of publications and posters to get the latest knowledge and insights within our focus areas: diabetes, obesity, NASH and gastrointestinal diseases.

Featured publications

INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Jonathan D. Roth, Michael Feigh, Sanne S. Veidal, Louise K.D. Fensholdt, Kristoffer T. Rigbolt, Henrik H. Hansen, Li C. Chen, Mathieu Petitjean, Weslyn Friley, Niels Vrang, Jacob Jelsing, Mark Young

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Kirstine S. Tølbøl, Maria N.B. Kristiansen, Henrik H. Hansen, Sanne S. Veidal, Kristoffer T.G. Rigbolt, Matthew P. Gillum, Jacob Jelsing, Niels Vrang, Michael Feigh

Mouse models of nonalcoholic steatohepatitis in preclinical drug development (Drug Discovery Today)

Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K.

Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

Tanja X. Pedersen, Thea Johansen, Lisbeth N. Fink, Niels Vrang, Thomas Secher

Novel Rat Model of Diabetic Nephropathy Displaying Tubular Fibrosis and Glomerular Alterations

Thomas Secher, Thea Johansen, Mette V. Østergaard, Philip J. Pedersen, Nora E. Zois, Tanja X. Pedersen, Niels Vrang, Lisbeth N. Fink

Novel 'Dual Hit' Rat Model of Diabetic Cardiomyopathy

The Preprohomone Expression Profile Of Enteroendocrine Cells Following Roux-en-Y Gastic Bypass in Rats

Lise Christine Biehl Rudkjær, Chen Chang, Kristoffer Rigbolt, Mechthilde Falkenhahn, Stefan Theis, Thomas Hübschle, Niels Vrang, Jacob Jelsing

Chemical Strategies for Half-life Extension of Biopharmaceuticals: Lipidation and its Alternatives

Esben Bech, Søren L. Pedersen, Knud Jensen

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson’s Disease

Fabricius K, Barkholt P, Jelsing J, Hansen HH

Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2

Jelsing J, Galzin AM, Guillot E, Pruniaux MP, Larsen PJ, Vrang N

The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion

Jelsing J, Larsen PJ, Vrang N

The imprinted gene neuronatin is regulated by metabolic status and associated with obesity

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

Vrang N, Larsen PJ

The brainstem preproglucagon system in a non-human primate (Macaca mulatta)

Vrang N, Grove K

Laser capture microdissection and quantitative-PCR analysis

Paulsen SJ, Larsen LK

Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight

Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Søeborg H, Knudsen LB

Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helixvariants of PYY3-36

Pedersen SL, Bhatia VK, Jurt S, Paulsson JF, Pedersen MH, Jorgensen R, Holst B, Stamou D, Vrang N, Zerbe O, Jensen KJ

Peptide release, side-chain deprotection, work-up, and isolation

Pedersen SL, Jensen KJ

Instruments for automated peptide synthesis

Pedersen SL, Jensen KJ

The effect of ileal interposition surgery on enteroendocrine cell numbers in the UC Davis type 2 diabetes mellitus rat

Hansen CF, Vassiliadis E, Vrang N, Sangild PT, Cummings BP, Havel P, Jelsing J

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

Hansen HH, Hansen G, Paulsen S, Vrang N, Mark M, Jelsing J, Klein T

Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis

Koehler JA, Baggio LL, Cao X, Abdulla T, Campbell JE, Secher T, Jelsing J, Larsen B, Drucker DJ

Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

Dalbøge LS, Pedersen SL, van Witteloostuijn SB, Rasmussen JE, Rigbolt KT, Jensen KJ, Holst B, Vrang N, Jelsing J

The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats

Skarbaliene J, Secher T, Jelsing J, Ansarullah, Neerup TS, Billestrup N, Fosgerau K

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes

Rhee NA, Wahlgren CD, Pedersen J, Mortensen B, Langholz E, Wandall EP, Friis SU, Vilmann P, Paulsen SJ, Kristiansen VB, Jelsing J, Dalbøge LS, Poulsen SS, Holst JJ, Vilsbøll T, Knop FK

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathyhttps://www.ncbi.nlm.nih.gov/pubmed/26746341

Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N

Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs

Hansen CF, Thymann T, Andersen AD, Holst JJ, Hartmann B, Hilsted L, Langhorn L, Jelsing J, Sangild PT

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease

Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

van Witteloostuijn SB, Pedersen SL, Jensen KJ

Neoglycolipids for prolonging the effects of peptides: Self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy

van Witteloostuijn SB, Mannerstedt K, Wismann P, Bech EM, Thygesen MB, Vrang N, Jelsing J, Jensen KJ, Pedersen SL

Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia

Mace ML, Gravesen E, Nordholm A, Hofman-Bang J, Secher T, Olgaard K, Lewin E

Neurturin and a GLP-1 analogue act synergistically to alleviate diabetes in Zucker diabetic fatty rats

Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model

Helboe L, Egebjerg J, Barkholt P, Volbracht C

A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

Schneider EL, Hearn BR, Pfaff SJ, Reid R, Parkes DG, Vrang N, Ashley GW, Santi DV

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues

Bech EM, Martos-Maldonado MC, Wismann P, Sørensen KK, van Witteloostuijn SB, Thygesen MB, Vrang N, Jelsing J, Pedersen SL, Jensen KJ

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice

van Witteloostuijn SB, Dalbøge LS, Hansen G, Midtgaard SR, Jensen GV, Jensen KJ, Vrang N, Jelsing J, Pedersen SL

Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control

Enteroendocrine K and L cells in healthy and type 2 diabetic individuals

Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, Jelsing J, Dalbøge LS, Vilmann P, Hassan H, Hendel JW, Poulsen SS, Holst JJ, Vilsbøll T, Knop FK

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

Pernille Wismann, Søren L. Pedersen, Gitte Hansen, Karin Mannerstedt, Philip J. Pedersen, Palle B. Jeppesen, Niels Vrang, Keld Fosgerau, Jacob Jelsing

INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Jonathan D. Roth, Michael Feigh, Sanne S. Veidal, Louise K.D. Fensholdt, Kristoffer T. Rigbolt, Henrik H. Hansen, Li C. Chen, Mathieu Petitjean, Weslyn Friley, Niels Vrang, Jacob Jelsing, Mark Young

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis (World Journal of Gastroenterology)

Kirstine S. Tølbøl, Maria N.B. Kristiansen, Henrik H. Hansen, Sanne S. Veidal, Kristoffer T.G. Rigbolt, Matthew P. Gillum, Jacob Jelsing, Niels Vrang, Michael Feigh

Body-weight lowering agents and their comparative metabolic and hepatic effects in obese mouse models of non-alcoholic fatty liver disease and steatohepatitis (Gubra poster)

Jacob Jelsing, Michael Feigh, Kirstine Sloth Tølbøl, Sanne Skovgård Veidal, and Niels Vrang

In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes (European Journal of Pharmacology)

Jolanta Skarbaliene, Kristoffer T. Rigbolt, Keld Fosgerau, Nils Billestrup

Mouse models of nonalcoholic steatohepatitis in preclinical drug development (Drug Discovery Today)

Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K.

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice (Molecular Metabolism)

Wismann P, Barkholt P, Secher T, Vrang N, Hansen HB, Jeppesen PB, Baggio LL, Koehler JA, Drucker DJ, Sandoval DA, Jelsing J.

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease (PLoS One)

Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N.

Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy (World Journal of Hepatology)

Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Kristoffer Tobias Gustav Rigbolt, Kirstine Sloth Tølbøl, Jacob Jelsing, Niels Vrang, Michael Feigh

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice (Journal of Diabetes Research)

Cucak H, Hansen G, Vrang N, Skarsfeldt T, Steiness E, Jelsing J.

Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass (Molecular Metabolism)

Barkholt P, Pedersen PJ, Hay-Schmidt A, Jelsing J, Hansen HH, Vrang N.

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents ((PLoS One))

Dalbøge LS, Pedersen PJ, Hansen G, Fabricius K, Hansen HB, Jelsing J, Vrang N.

Neuromedin U inhibits food intake partly by inhibiting gastric emptying (Peptides)

Dalbøge LS, Pedersen SL, Secher T, Holst B, Vrang N, Jelsing J.

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease (Journal of Alzheimer’s Disease)

Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, Pyke C, Knudsen LB, Farr SA, Vrang N.

Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain (Endocrinology)

Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, Knudsen LB, Vrang N, Grove KL.

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss (The Journal of Clinical Investigation )

Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L.

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat (The Journal of Pharmacology and Experimental Therapeutics)

Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, Klein T, Mayoux E.

The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice (The Journal of Pharmacology and Experimental Therapeutics)

Dalbøge LS, Almholt DL, Neerup TS, Vrang N, Jelsing J, Fosgerau K.

Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion (PLoS One)

Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N.

Characterisation of age-dependent beta cell dynamics in the male db/db mice (PLoS One)

Dalbøge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, Fosgerau K, Jelsing J.

Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats (PLoS One)

Hansen CF, Bueter M, Theis N, Lutz T, Paulsen S, Dalbøge LS, Vrang N, Jelsing J.

Novel insight into the distribution of L-cells in the rat intestinal tract (American Journal of Translational Research)

Hansen CF, Vrang N, Sangild PT, Jelsing J.

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice (Journal of Endocrinology)

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.

Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats (Acta Pharmacologica Sinica)

Hansen G, Jelsing J, Vrang N.

Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function (Journal of Anatomy)

Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J.

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 2650

CRO Services

Diabetes Obesity NASH Gastrointestinal diseases

Partner Programs

Diabetes Obesity NASH Gastrointestinal diseases

Methodology

In vivo pharmacology Histology & stereology NGS & bioinformatics Ex vivo assays Molecular pharmacology Petide chemistry

Publications

Publications

About us